Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors
2023-504084-17-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of alectinib in Anaplastic lymphoma kinase fusion-positive solid tumor and central nervous system primary tumor, sponsored by Roche. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence and severity of adverse events (Part 1) and 2 more. Planned start Jul 2024; status: authorised.
02
Drugs
alectinib
03
Conditions
Anaplastic lymphoma kinase fusion-positive solid tumorcentral nervous system primary tumor
Beyond the preview
Go deeper on 2023-504084-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504084-17-00.